93 results about "Vaccine efficacy" patented technology

A system and method to predict and assess immunogenicity, especially prior to on-set of immunogenic conditions. Also disclosed are methods to identify relevant peptides associated with the formation of antibodies in patients treated with a given protein therapeutic. In various aspects, the present application is directed to methods of determining the immunological compatibility of a subject with a therapeutic agent such as a proteinaceous therapeutic agent, methods of determining vaccine efficacy by determining the immunological compatibility of a subject with a therapeutic agent, and selecting a therapeutic agent for a subject in need of treatment. Methods of designing a therapeutic agent with reduced immunogenicity for a subject and methods for designing vaccines with enhanced immunogenicity for a subject are also contemplated.

Compositions and methods for modulating immunity and vaccine efficacy in animals are disclosed. The compositions and methods utilize probiotic organisms, specifically probiotic Enterococcus strains, and are particularly applicable to felines.

A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or "marker" DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

A composition and method for formulating and delivering an adjuvanted immunological active agent, especially a vaccine, wherein adjuvant coagulation and concomitant loss of vaccine efficacy enhancement is mitigated or avoided. The adjuvanted, immunologically-active agent can be subjected to freezing, drying, freeze-drying, or lyophilization, and when reconstituted, retains a high level of potency. The present invention further provides for a composition and method for formulating and delivering a stable, adjuvanted, immunologically-active agent capable of being deposited on a transdermal delivery device or microprojection or array thereof.

Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic Enterococcus bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in amounts suitable for the intended purpose. In certain embodiments, the probiotic is Enterococcus faecium strain NCIMB 10415 (SF68) and the animal is a feline.

A method of disassembly/reassembly of papillomavinis VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or marker" DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.

Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.

The invention relates to a circulating water aquaculture device for aquatic animal aquaculture and drug application evaluation. The circulating water aquaculture device integrates aquatic animal aquaculture, water treatment and water quality monitoring, can achieve circulating water or still water aquaculture of fresh water or seawater aquatic animals, treatment and drainage of aquaculture water and aquaculture water physical and chemical parameter detection and can guarantee that the aquaculture environment is excellent, and the experiment condition is controllable in the drug application evaluation (for example, vaccine efficacy evaluation) process.

The present invention discloses a method for quantification of 146s content in foot-and-mouth disease antigen by using a liquid chromatography detection system. The method comprises: adopting protamine sulfate to purify virus, adopting PEG6000 to concentrate the virus, carrying out sucrose density gradient ultracentrifugation on the concentrated virus, adopting a liquid chromatography detection system to detect an absorption peak of the centrifugated sample at a wavelength of 259 nm, and calculating 146S content according to the following formula: C=FRS/76Wb. The method can be used for determination of the 146S content in various types of foot-and-mouth disease antigens. With quantification of the 146S content in the foot-and-mouth disease antigen, foot-and-mouth disease vaccine preparation can be guided, vaccine efficacy can be indirectly evaluated, and major guiding significances are provided for enhancing quality of the foot-and-mouth disease vaccine in our country.

Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or “marker” DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

A method for the discovery, development and clinical application of multidimensional multiplex synthetic biomarker assays based on patterns of cellular response.

After stimulation or inhibition, a selected multiplicity of cell types are assayed for a multiplicity of cellular or molecular responses, and known machine learning techniques are used to synthesize the cellular responses into an optimized clinical biomarker. The computationally derived algorithm includes the relationships within and between the component steps so as to produce an optimized synthetic clinical biomarker. During discover of the assay one or more of the component steps are repeated iteratively until a final clinically optimized algorithm is produced.

Such a multidimensional multiplex cell response assay may provide improved diagnostic performance with respect to entities such as immune status, infection, and antibiotic and vaccine efficacy, among others.

The invention discloses a spinner bottle production method of inactivated singapore grouper iridovirus (SGIV) vaccine. The production method comprises spinner bottle culture of cells, amplification and harvest of viruses and inactivation of the viruses. By using the spinner bottle production method of the inactivated SGIV vaccine disclosed by the invention, the inactivated SGIV vaccine can be produced on a large scale, and the production cost is low and the labor intensity is small since the production is industrial streamline production; after vaccine inspection on the produced inactivated SGIV vaccine, the inactivated SGIV vaccine is safe from the aspect of cell level and fish level; vaccine efficacy detection proves that the relative protection rate of the inactivated SGIV vaccine provided by the invention is 87.0-95.7%, so that inactivated SGIV vaccine provides obvious protection for immune grouper, the immune protection efficacy is good and quality between batches is stable.

The methods of the present invention allow for the measurement of proliferation, clonal expansion trafficking and/or recruitment of lymphocytes into lymphoid tissue in an in vivo setting. Proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes are measured by using stable isotopes to label newly synthesized DNA, isolating the newly-labeled DNA, and quantifying enrichment of the isolated DNA with mass spectrometry or other appropriate techniques. Such methods are useful in screening candidate drugs for stimulatory or inhibitory effects on proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes. The methods also allow for the discovery of therapeutic agents in disorders of immune regulation such as HIV infection and for optimizing vaccine efficacy.

Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.

The present invention provides methods for establishing standards for Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention also provides methods for reproducing Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention further provides methods for preparing multibacterial vaccines. Also provided are multibacterial vaccines prepared in accordance with these methods, and methods for treating and/or preventing disorders using these multibacterial vaccines. In addition, the present invention provides methods for predicting the efficacy of multibacterial vaccines, and methods for enhancing the efficacy of multibacterial vaccines.

The invention discloses a method for preparing vaccine vectors for swine from swine IgG1 Fc recombinant baculoviruses, and belongs to the field of biological medicine. The method includes connecting cloned swine IgG Fc genes and swine fever virus E2 genes to baculovirus surface display vectors to obtain recombinant transfer vectors; enabling the recombinant transfer vectors to acquire recombinant baculovirus Bacmid vectors by means of Tn7 transposition; enabling the recombinant baculovirus Bacmid vectors to carry out transfection on insect cells by the aid of a liposome process, collecting culture supernatants to acquire recombinant baculoviruses, infecting the insect cells by the recombinant baculoviruses, and collecting cells to carry out Western blot analysis and confocal microscopic analysis on the cells; enabling recombinant baculovirus swine fever vectors to carry out vaccine efficacy tests on the swine. The method has the advantages that surface display swine IgG Fc recombinant baculoviruses prepared by the aid of the method is high in survival ability in swine serum and can be prevented from being removed by serum complements, and accordingly the contents of effective antigens of vaccine immunity can be increased.

A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or "marker" DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.

The invention relates to a clostridium perfringens Beta toxin recombination subunit vaccine and a production method thereof. The prepared clostridium perfringens Beta toxin recombination subunit vaccine is produced by using a recombination clostridium perfringens Beta toxin protein which is processed by codon optimization and contains 4 amino acid mutations, namely integrity and spatial conformation of a natural toxin protein are reserved in the greatest degree, so immunogenicity of the natural toxin protein is kept, and a biological potential safety hazard caused by the single amino acid mutation is avoided. The vaccine further has the advantages of simple preparation process, low immunizing dose, good vaccine efficacy and the like. Compared with a current commercial clostridium perfringens natural toxin inactivated vaccine in China, a bio-safety risk in a vaccine production process is greatly reduced. The vaccine is a perfect candidate vaccine for updating a current C-type clostridium perfringens toxin vaccine in China. In addition, while a mixed vaccine is prepared by the vaccine with other antigens, the mixed vaccine can be prepared without increasing a using dose of the mixedvaccine.

The invention relates to a clostridium perfringens epsilon toxin recombinant subunit vaccine and a production method thereof. The clostridium perfringens epsilon toxin recombinant subunit vaccine prepared by the invention is produced by adopting recombinant clostridium perfringens epsilon toxin protein subjected to codon optimization and containing three amino acid mutations, and the integrality and a spatial conformation of the natural toxin protein are retained maximally, so that the immunogenicity is maintained, and the bio-safety risk brought by a single amino acid mutation is avoided. Thevaccine also has the advantages of simple preparation process, low immunizing dose, higher vaccine efficacy compared with an existing vaccine; compared with a currently commercial clostridium perfringens natural toxin inactivated vaccine in China, the bio-safety risk during a vaccine production process is greatly reduced, and the clostridium perfringens epsilon toxin recombinant subunit vaccine is an ideal candidate vaccine upgraded and updated based on a current D type clostridium perfringens toxin vaccine in China; and when the vaccine and other antigens are used for jointly preparing a mixed vaccine, the mixed vaccine can be prepared without the need for increasing the dosage of the mixed vaccine.